MedTrace Logo

HPA Antibodies and the Distribution of Antigen and Antibodies

NCT03408158 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6170

Last updated 2021-08-12

No results posted yet for this study

Summary

By detecting platelet antibodies of participants and then further to identify their genotype and analyzing laboratory examination, the investigators will obtain positive frequency of HPA antibodies, the distribution of HPA antigen and antibodies, effect of matching platelet transfusion, all of which in favor of draw a conclusion that it is very important to carry out HPA antibody detection and matching transfusion in early phase.

Conditions

  • Blood Disease
  • Platelet Refractoriness
  • Antibody-mediated Rejection

Interventions

PROCEDURE

same type infusion of main HPA antigen

Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not

Sponsors & Collaborators

  • LanZhou University

    collaborator OTHER

  • First Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • Hunan Provincial People's Hospital

    collaborator OTHER

  • The Fourth Affiliated Hospital of China Medical University

    collaborator OTHER

  • The Third Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Guangzhou First People's Hospital

    lead OTHER

Principal Investigators

  • Yaming Wei, Doctor · Director of Blood Transfusion Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03408158 on ClinicalTrials.gov